Concert dumps schizophrenia drug CTP-692 after failing phase 2

A phase 2 clinical trial of Concert Pharmaceuticals’ CTP-692 in schizophrenia patients has missed its primary endpoint. The setback led Concert to stop development of the deuterated form of D-serine and focus on a phase 3 treatment for a form of hair loss.